The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial
Aliment Pharmacol Ther. 2022 Jun;55(12):1512-1523.doi: 10.1111/apt.16953. Epub 2022 May 10.
1Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
2Tayside Clinical Trials Unit, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
3Directorate of Public Health, NHS Tayside, Kings Cross Hospital, Dundee, UK.
4Department of Microbiology and Infectious Diseases Cardiff, Public Health Wales, Cardiff, UK.
5Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia.
6Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
7Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK.
8Department of Gastroenterology, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.
9AbbVie Ltd, AbbVie House, Maidenhead, UK.
Abstract
Background: Conventional healthcare models struggle to engage those at risk of hepatitis C virus (HCV) infection. This international study evaluated point-of-care (PoC) HCV RNA diagnostic outreach and direct-acting antiviral (DAA) treatment for individuals receiving opioid agonist therapy (OAT) in community pharmacies.
Aims: We assessed the effectiveness of a roving nurse-led pathway offering PoC HCV RNA testing to OAT clients in community pharmacies relative to conventional care.
Methods: Pharmacies in Scotland, Wales, and Australia were randomised to provide PoC HCV RNA testing or conventional referral. Pharmacists directed OAT clients to on-site nurses (intervention) or local clinics (control). Infected participants were treated with DAAs, alongside OAT. Primary outcome was the number of participants with sustained virologic response at 12 weeks (SVR) and analysed using mixed effects logistic regression in the intention-to-treat (ITT) population.
Results: Forty pharmacies were randomised. The ITT population contained 1410 OAT clients. In the conventional arm (n = 648), 62 (10%) agreed to testing, 17 (27%) were tested, 6 (35%) were positive and 5 (83%) initiated treatment. In the intervention arm (n = 762), 148 (19%) agreed to testing, 144 (97%) were tested, 23 (16%) were positive and 22 (96%) initiated treatment. SVR was obtained by 2 (40%; conventional) and 18 (82%; intervention). Intervention arm participants had higher odds of testing, OR 16.95 (7.07-40.64, p < 0.001); treatment, OR 4.29 (1.43-12.92, p = 0.010); and SVR, OR 8.64 (1.82-40.91, p = 0.007).
Conclusions: Nurse-led PoC diagnosis in pharmacies made HCV care more accessible for OAT clients relative to conventional care. However, strategies to improve testing uptake are required.